NHS patients to benefit from first full access deal in Europe for new CAR-T therapy

NICE has issued final draft guidance recommending the therapy via the Cancer Drugs Fund for relapsed or refractory mantle cell lymphoma, previously treated with a BTK inhibitor.

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date

Existing members Sign in